According to the Complaint, Progenics Pharmaceuticals, Inc. is an oncology company focused on the development and commercialization of targeted medicines and artificial intelligence to find, fight and follow cancer. The Company’s pipeline includes therapeutic agents designed to precisely target cancer and prostate-specific membrane antigen targeted imaging agents for prostate cancer.

This action stems from a proposed transaction announced on October 2, 2019, pursuant to which Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., will acquire Progenics in an all-stock transaction.

On November 12, 2019, Defendants caused the Form S-4 Registration Statement (the "S-4") to be filed with the SEC in connection with the Proposed Transaction. The S-4 solicits the Company’s shareholders to vote in favor of the Proposed Transaction. The Complaint alleges that the S-4 is materially incomplete and misleading, in violation of Sections 14(a) and 20(a) of the Exchange Act.

This case was voluntarily dismissed on March 5, 2020. A related case continues under Docket 19-CV-21200 in the District of New Jersey. Plaintiff filed an amended Complaint on April 21. On April 24, this case was transferred to the Southern District of New York. On June 11, this case was voluntarily dismissed.